Quest Diagnostics Inc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Quest Diagnostics Inc (DGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-26
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.60%, a 6.98% increase from fiscal 2024.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.30%, a 2.38% increase from fiscal 2023.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.20%, a 110.00% increase from fiscal 2022.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.00%, a 233.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2025-12-31 | 4.60% 10-K · filed 2026-02-26 |
| 2024-12-31 | 4.30% 10-K · filed 2026-02-26 |
| 2023-12-31 | 4.20% 10-K · filed 2026-02-26 |
| 2022-12-31 | 2.00% 10-K · filed 2025-02-20 |
| 2021-12-31 | 0.60% 10-K · filed 2024-02-22 |
| 2020-12-31 | 1.50% 10-K · filed 2023-02-21 |
| 2019-12-31 | 2.50% 10-K · filed 2022-02-28 |
| 2018-12-31 | 2.80% 10-K · filed 2021-02-22 |
| 2017-12-31 | 2.10% 10-K · filed 2020-02-20 |
| 2016-12-31 | 1.40% 10-K · filed 2019-02-21 |
| 2015-12-31 | 1.70% 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |